Newcastle man sheds nearly 4.5 stone with MAN v FAT programme
Luke Foster, 42, weighed almost 23 stone when he first joined MAN v FAT Newcastle in January 2023.
After foot problems forced him to stop for a few months, he rejoined in August 2024 and says he has never looked back.
Mr Foster said: "MAN v FAT has had a massive impact on my lifestyle.
"I used to be very much, go to work, come home, and do nothing.
"Now I am playing football twice a week and have just started to go to the gym again.
"It has helped my relationship with food.
"I really watch what I eat.
"Don't get me wrong, I still have a drink on a Friday night, but it's not as excessive as it once was."
The Newcastle MAN v FAT Football club, which meets every Monday evening at NUCASTLE, the Newcastle United Foundation on Diana Street, has helped 56 local men lose more than 31 stone in excess weight between them in the last year.
MAN v FAT is a weight loss initiative that aims to help overweight and obese men with a BMI of more than 27.5 lose unwanted weight through weekly football and lifestyle coaching sessions.
At sessions, players are weighed, followed by a 30-minute game of six-a-side football, with extra goal bonuses awarded to teams based on their weight loss.
A team's total weight loss and match scores then contribute to its position within a club's overall league table.
Mr Foster said: "I would recommend MAN v FAT.
"Everyone is there to help you, as they are all in the same boat and, if anything, it will get you moving.
"That's the best thing about it.
"I now play on Monday evenings and have started a couple of social games as well."
According to the Newcastle City Council Director of Public Health Report 2023, 64 per cent of adults aged 18 and over in Newcastle are classified as overweight or obese (https://www.newcastle.gov.uk/sites/default/files/NCC%20Director%20of%20Public%20Health%20Annual%20Report%202023.pdf).
Richard Crick, head of MAN v FAT, said: "Luke and all the guys at our Newcastle club have been drawn to our programme through a love of football and being part of a team.
"What they have gone on to achieve both individually and as a key part of the club we have in Newcastle is fantastic.
READ MORE:
Royal Visit Durham: Hundreds turn out for King and Queen
HMP Frankland prison officer still in hospital after attack
Santoro's in Yarm hits market months after shock closure
"Our Newcastle club has spaces for new players, so if you're looking to make a positive change to your lifestyle, get in touch."
To find out more about MAN v FAT Football and to locate your closest club, visit www.manvfat.com/football.
A rugby club offering on the MAN v FAT model is also being rolled out, with more information available at https://manvfatrugby.com/.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
5 Things People Get Wrong About Single-Parent Adoption and Foster Care
Reviewed by Sacha Coupet, PhD, JD Key Points Single people who want to foster or adopt a child for a wide variety of reasons, but there might be some misconceptions about their resources and capabilities as caregivers In fact, single people have both the opportunity and the ability to foster or adopt children Experts say that while the adoption process might be intimidating and require commitment, its not an insurmountable process for single people and can be highly rewardingFamilies come in all shapes and sizes–including families built with the help of adoption. Every year, around 100,000 children are adopted in the United States. Single-parent adoption makes up about 28% of all parents adopting from foster care between 2017-2019. Of the 1.8 million adopted children in the U.S, 38% joined their families through private domestic adoptions, and 25% were adopted internationally. While most adoption stories include two parents, adopting a child as a single parent is still a wonderful way to start a family—unfortunately, many misconceptions about single-parent adoption linger. Rita Soronen, President & CEO of Dave Thomas Foundation for Adoption, says that, of those polled in their 2022 Adoption and Foster Care Attitudes Survey, only 48% felt single parents could provide a healthy environment for an adopted child. But experts say the reality is much different. 'There is simply no reason that a single parent can't provide exactly the right safe, nurturing and thriving environment for an adopted child,' she explains. What are the misconceptions about single-parent adoption–and more importantly, how can these misconceptions be dispelled? Here, we gathered 5 ideas about single-parent adoption that experts say simply aren't true."'We have so many myths and misconceptions surrounding adoption and foster care adoption. We simply need to encourage everyone, from potential adoptive parents to policymakers and practitioners, to focus on the fact that every child needs and deserves the stability and support of a permanent family, no matter their age, the circumstances that moved them into foster care, or how they identify themselves.'" Rita Soronen, President & CEO of Dave Thomas Foundation for AdoptionSingle Parents Aren't Favored to Adopt Some parents might think that adopting as a single parent drastically reduces their chances of adopting through foster care or private adoption. But that couldn't be further from the case. All 50 states have legislation in place allowing single-parent adoption. 'Adoption, including adopting from foster care, is open to all types of family structures. People find themselves single for myriad reasons—single by choice, haven't met the right person, divorce, widowed—and these situations should not stop someone from starting a family if they choose,' Soronen explains. Single parents go through the same steps as couples in the adoption process, she continues, which may differ community to community. 'Of course, single parents are taking on all the work of parenting, so it is important to identify and have a support system in place,' Soronen says. Indeed, single-parent adoption is on the rise. In the 1970s, single-parent adoptions only constituted at most 4%—now single-parent adoption is nearing 30%. You Have to Be Married to Be a Good Parent Let's face it: a stigma around single parents exists. Traditional media amplifies the so-called 'nuclear family': a family with a mother and father at its head and with two or more kids. But increasingly, families don't fit into this narrow framework. As of 2019, nearly a quarter of children live in single-parent households. 'The biggest myth is that you can't adopt or be successful as a single parent, and it's simply not true. Families who adopt are as unique and diverse as the children in their care, and children in foster care do not need to wait for some specific notion of family,' says Soronen. Brittany, former foster parent, and now mom to a teen girl, Kyleigh, explained how long the process of foster-to-adoption can take. It takes serious commitment to build a family, especially through adoption. 'Kyleigh came into foster care March 2021 and was with me until December 2021,' Brittany says. 'She was in a potential adoptive placement until March 2022 but returned to my home abruptly when the family changed their mind. Then she was with me until [Brittany adopted her] in November 2023." At the beginning of the process, Brittany says she experienced feelings of shame and self-consciousness when she decided she wanted to become a parent. But Brittany didn't want to get married—and decided to step into a parental role anyway. 'I was in my late twenties and hadn't met a man I was interested in marrying; but I wanted to be a mom, even if it was temporary. I knew there were kids who needed a safe, stable home and I had the means to provide it,' she says. Like Brittany, many single people choose to adopt or foster for myriad reasons. Perhaps they don't want to get married, or experienced the loss of a partner. Whatever the case, being single and wanting to adopt is valid. Anyone who has the capacity to love and care for a child can become a parent. You Have to Be Wealthy to Adopt While building a family as a single parent can be a challenge financially, you don't have to have unlimited resources to make it work. In fact, many families are choosing to have children later in life, partially because of economic security. 'You don't have to be a stereotypical, two-parent family, you don't have to own your home or be wealthy,' Soronen explains. While domestic adoption can be quite costly, running from $20,000-$45,000, a cost which might take some financial planning on the part of a prospective single parent, foster-to-adopt can be accomplished for under $2600, and in some cases is entirely free through the public welfare system. 'Children need loving individuals in their lives who are willing to meet the challenges of parenting, who understand the journey the child has experienced while in foster care and who will make a lifetime commitment to caring for and nurturing them,' Soronen says. Single-Parent Support Systems Are Lacking When Brittany decided to foster Kyleigh, her main concern was whether she could provide the support her child needed. 'However, I learned those needs could be met in ways other than having a partner or spouse. I had friends, both male and female, who stepped up when I needed help,' she explains. Not only could she lean on her friends when she needed someone to talk to, but they helped her with pick ups and drop offs, helped her with shopping, and even dropped off meals. While this looks different from a traditional family dynamic, Brittany made it work for Kyleigh. 'We had a very solid community and support system around us,' she says. Soronen concurs: Successful, loving, and supportive families look different for everyone, and single parents are more than capable of growing a good support network. 'Family is the essential structure that we all need when life is challenging, when there is cause for celebration of life's special moments and when we simply need a place to rest. And who are we to say what that family should look like?' Soronen says. Single-Parent Households Can't Provide Enough Love for a Child It's a backwards and outdated assertion that single-parent homes can't offer enough love to an adopted child. Kyleigh came from a difficult situation: After her father died, her stepmother could not take care of her. She entered the foster care system at 12 years old–until Brittany brought her into her home. 'The first few days I was with Brittany I was really scared about what was going to happen to me but in the end I ended up being her forever daughter,' she explains. Brittany says that though she faced a serious learning curve, becoming Kyleigh's mom is the best thing she's ever done. 'I've never regretted saying yes to Kyleigh,' she says. In the end, the wellbeing of a child in an adoptive household, no matter what the configuration of parents, matters most. For Kyleigh, coming into Brittany's home was a wonderful turning point. 'Brittany is the most amazing mom a teenage girl can ever have,' she says. Read the original article on Parents Solve the daily Crossword
Business Wire
a day ago
- Business Wire
NeoGenomics Launches PanTracer LBx, Expanding Access to Comprehensive Genomic Profiling with Liquid Biopsy
FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling (CGP) test, expanding the company's PanTracer portfolio. PanTracer LBx is a noninvasive test designed to support therapy selection, trial matching, and longitudinal monitoring, empowering data-driven decisions even when tumor tissue is limited or unavailable. 'The launch of our liquid biopsy test positions us at the forefront of the precision oncology market,' said Tony Zook, Chief Executive Officer, NeoGenomics. 'As demand grows for faster, less invasive, and more accessible genomic testing, PanTracer LBx expands our addressable market, enhances our clinical portfolio, and opens new revenue streams in both therapy selection, trial matching, and disease monitoring. It's a strategic milestone that underscores our commitment to sustainable growth and clinical leadership.' Using circulating tumor DNA (ctDNA) from a simple blood draw, PanTracer LBx provides access to biomarker information when tissue samples are insufficient or unavailable. The test is designed to offer a seven-day turnaround time and analyze over 500 genes, including MSI and bTMB, to deliver timely, actionable insights. When indicated, it can be ordered as a standalone option, as a reflex when tissue testing fails, or concurrently with tissue analysis. Clinical applications include therapy selection, trial matching, and longitudinal monitoring. PanTracer LBx strengthens NeoGenomics' pan-solid tumor CGP portfolio, working seamlessly with tissue-based options like PanTracer Tissue, providing a testing strategy across a range of solid cancers. Complemented by a broad portfolio of testing services and dedicated clinical support, the launch expands NeoGenomics' position in the growing $3–5 billion liquid biopsy market and advances its goal of delivering deep insights to more patients across diverse care settings. About NeoGenomics, Inc. NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom. Forward-Looking Statements This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as 'anticipate,' 'expect,' 'plan,' 'can,' 'could,' 'would,' 'may,' 'will,' 'believe,' 'estimate,' 'forecast,' 'goal,' 'project,' 'guidance,' 'potential' and other words of similar meaning, although not all forward-looking statements include these words. These forward-looking statements address various matters, including statements regarding the potential impact of PanTracer™ LBx in oncology treatment and clinical trial enrollment. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Applicable risks and uncertainties include, among others, the extent of use by oncologists and biopharma companies of PanTracer™ LBx, the speed and utility of the results generated, and the risks identified under the heading "Risk Factors" contained in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company's other filings with the Securities and Exchange Commission. We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at and in the 'Investors' section of our website at for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
Business Upturn
3 days ago
- Business Upturn
Biocytogen Upgrades Preclinical Service Platform and Launches Revamped Global Website
Business Wire India Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a comprehensive upgrade to its preclinical business division. The upgrade features an expanded portfolio of genetically engineered animal models—including target-humanized, immune-humanized, transgenic, and immunodeficient mice—alongside a full suite of preclinical services such as efficacy studies, PK/PD analysis, biomarker evaluation, and non-GLP toxicology testing. In parallel, the company also launched its new official website ( featuring an intuitive structure, enriched content, and an optimized multilingual user experience to serve global clients and partners better. Extensive Model Portfolio with Over 1,100 Target-Humanized Mouse Models In 2021, Biocytogen launched the 'BioMice' sub-brand to advance its portfolio of genetically engineered mouse models. Leveraging its proprietary gene-editing platform, the company has developed more than 1,100 target-humanized mice. These models are generated using precise in situ gene replacement technology, which substitutes mouse genes with human sequences while preserving endogenous gene regulation. This approach enables a more accurate simulation of human physiological and pathological conditions, establishing BioMice as the gold-standard platform for evaluating the efficacy and safety of various therapeutic modalities, including antibody drugs, cell therapies, bispecific/multispecific antibodies, ADCs, and oligonucleotide-based treatments. The company has established high-value disease models for oncology, autoimmune, metabolic, and neurological disorders, including CD3 (TCEs), HER2 (TAAs), TL1A (IBD), TSLP (AD), GLP1R (muscle gain/weight loss), and TFR1 (BBB delivery). These models are widely used for target validation, mechanistic studies, and preclinical evaluations. To date, safety data generated from these models have supported 15 IND approvals by China's NMPA and 5 IND approvals by the U.S. FDA (including 4 dual submissions). Biocytogen also offers immune-humanized mouse models (e.g., huPBMC-B-NDG, huHSC-B-NDG, huHSC-B-NDG hIL15, and huPBMC-B-NDG MHC I/II DKO plus), transgenic mice, and immunodeficient strains to support evaluations of immuno-oncology agents, T/NK cell therapies, and immunostimulatory drugs, building a comprehensive and multi-dimensional model portfolio. Global Animal Supply Network Supporting Efficient Preclinical Research Biocytogen operates three AAALAC-accredited animal facilities in Haimen (Jiangsu), Daxing (Beijing), and Boston (USA), covering a total area of 55,000 m² and offering an annual supply capacity of over 800,000 laboratory animals. With a robust quality control system and standardized microbial monitoring, Biocytogen has established an international distribution network spanning Asia, Europe, and North America. The company's mouse models have been successfully delivered to clients in over 20 countries and regions, providing reliable model support for global drug development efforts. Integrated Preclinical Services to Accelerate IND Filing and Clinical Translation Leveraging its proprietary animal models, Biocytogen provides one-stop, non-GLP preclinical products and services, including in vivo efficacy testing, PK/PD analysis, biomarker assessment, and early toxicology studies. With a vast collection of CDX and PDX tumor models and customizable study designs, Biocytogen serves over 20 therapeutic areas—including solid tumors, hematologic malignancies, autoimmune diseases, metabolic disorders, and neurodegenerative diseases—and supports a variety of drug modalities such as antibodies, small molecules, ADCs, bispecifics, cell therapies, nucleic acids, and vaccines. As of now, Biocytogen has completed more than 5,300 drug evaluation studies for nearly 900 pharmaceutical and academic institutions worldwide. Over One Million Fully Human Antibodies Empowering Antibody Drug Discovery Beyond preclinical services, Biocytogen also leads in antibody discovery through its proprietary RenMice® platforms—including RenMab™ (fully human antibody), RenLite® (common light chain), RenNano® (VHH antibody), RenTCR™ (fully human TCR), and RenTCR-mimic™ (fully human TCR-mimic antibody). The company has built a library of over one million fully human antibody sequences against more than 1,000 potential therapeutic targets, with diverse structures and functional profiles. As of December 31, 2024, Biocytogen has signed approximately 200 drug co-development, licensing, or transfer agreements, including over 50 target-based RenMice® platform collaborations with multinational pharmaceutical companies. Multiple clinical-stage antibody candidates have also been successfully out-licensed to global partners. Biocytogen's integrated capabilities in antibody discovery, screening, and engineering are accelerating the transition from target validation to clinical candidate selection, empowering global biopharmaceutical innovation. New Official Website Launched to Serve Global Clients To enhance global service capabilities, Biocytogen has officially launched its new website: . Designed for a clean and intuitive user experience, the new site features streamlined architecture, upgraded content organization, improved search functionality, and multilingual support in Chinese, English, Japanese, and Korean. Structured around its two main business divisions—BioMice® for preclinical products and services and RenBiologics™ for antibody discovery and collaboration—the site offers a comprehensive overview of Biocytogen's model products, antibody assets, project portfolios, and service capabilities. It provides an efficient and direct information portal for global partners and supports the company's ongoing internationalization strategy. About Biocytogen Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab™/ RenLite®/ RenNano®/ RenTCR-mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash
